See other companies on Otta
Ionpath
Ion beam imaging technology for medical discovery
- 21-100 employees
- Healthcare
- B2B
- Deep Tech
- Analytics
- Computer Vision
- Science
- MedTech
- 960 Obrien Dr, Menlo Park, California 94025, USA
Jump to section
Company mission
Ionpath's mission is to advance precision medicine.
2% employee growth in 12 months
Otta's take
Sam Franklin
CEO of Otta
Advancements in tissue imaging technologies have enabled scientists to characterize both healthy and diseased tissues at a single-cell level, which is crucial in research to fight various diseases. Ionpath's Multiplexed Ion Beam Imaging (MIBI) system offers new insights into single cells in complex tissue microenvironments, delivering high-definition, high-quality cell profiling.
Ionpath has raised considerable funding over the years that has enabled it to expand operations to meet the growing demand for in-depth imaging. Interestingly, in 2023 the company shifted to focus on its services business, and has suspended the sale of its MIBIscope ,which was the first product of its kind on the market.
Ionpath's new CEO, who will lead this new direction, stated that the reasoning behind the shift was to "lower the barriers to using MIBIscope". The company has found there is high demand for quality cell profiling data, particularly from the drug discovery and development market - which represents a rich target for Ionpath moving forward.
Benefits
- Stock options
- 401k
- Work from home opportunities
Funding (1 round)
Sep 2020
$18m
SERIES B
$18m
Total funding
Founders
David Summa
(CEO, not founder)Venture Partner at Genoa Ventures, Partner at Business Model Innovations, and Advisor at Peaxy. Former Executive Director of the Alliance of CEOs.